Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…, 5

In forcesince 31 Dec 2020

…

Changed on 31 Dec 2020

1. A Committee for Medicinal Products for Human Use is hereby established. The Committee shall be part of the Agency. 2. Without prejudice to Article 56 or to other tasks which Union law may confer on it, the Committee for Medicinal Products for Human Use shall be responsible for drawing up the opinion of the Agency on any matter concerning the admissibility of the files submitted in accordance with the centralised procedure, the granting, variation, suspension or revocation of an authorisation to place a medicinal product for human use on the market in accordance with the provisions of this Title, and pharmacovigilance. For the fulfilment of its pharmacovigilance tasks, including the approval of risk management systems and monitoring their effectiveness provided for under this Regulation, the Committee for Medicinal Products for Human Use shall rely on the scientific assessment and recommendations of the Pharmacovigilance Risk Assessment Committee referred to in Article 56(1)(aa). 3. At the request of the Executive Director of the Agency or the Commission representative, the Committee for Medicinal Products for Human Use shall also draw up an opinion on any scientific matter concerning the evaluation of medicinal products for human use. The Committee shall take due account of any requests by Member States for an opinion. The Committee shall also formulate an opinion whenever there is disagreement in the evaluation of medicinal products through the mutual recognition procedure. The opinion of the Committee shall be made publicly accessible.…

  1. 31 Dec 2020 – todayin force
  2. 28 Jan 2019 – 31 Dec 2020earlier wording
  3. 2 Jul 2012 – 28 Jan 2019earlier wording
  4. 26 Jan 2007 – 2 Jul 2012earlier wording

Versions are held from 26 Jan 2007; the article may be older.